Brokers Set Expectations for TBPH FY2028 Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Investment analysts at HC Wainwright issued their FY2028 EPS estimates for shares of Theravance Biopharma in a report issued on Tuesday, February 25th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will earn $1.11 per share for the year. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma’s FY2029 earnings at $3.87 EPS.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $8.97 on Wednesday. The firm has a market capitalization of $441.09 million, a price-to-earnings ratio of -8.88 and a beta of 0.21. Theravance Biopharma has a one year low of $7.44 and a one year high of $10.90. The company has a 50 day moving average price of $9.36 and a 200 day moving average price of $8.91.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ballentine Partners LLC purchased a new stake in shares of Theravance Biopharma during the third quarter valued at approximately $104,000. China Universal Asset Management Co. Ltd. boosted its holdings in Theravance Biopharma by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,696 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in Theravance Biopharma by 12.6% in the third quarter. GSA Capital Partners LLP now owns 229,780 shares of the biopharmaceutical company’s stock valued at $1,852,000 after purchasing an additional 25,691 shares during the last quarter. Algert Global LLC acquired a new stake in Theravance Biopharma during the 3rd quarter valued at approximately $851,000. Finally, Quantbot Technologies LP purchased a new stake in Theravance Biopharma during the 3rd quarter worth approximately $60,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares in the company, valued at approximately $2,786,085. This represents a 1.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.